In a report published Wednesday, Jefferies reiterated its Hold rating on Boston Scientific Corporation BSX, and raised its price target from $6.00 to $7.60.
Jefferies noted, “BSX posted another negative quarter as soft results in CRM and DES resulted in the company posting -1% revenue growth. While stabilization in these two franchises, comprising over half of revenues, remains elusive, the company believes 2013 is when growth tacks back into positive territory. Maintain Hold.”
Boston Scientific Corporation closed on Tuesday at $6.86.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in